2 recruiting, 1 not yet recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Adebrelimab Injection: new trials by email Literature Review of Adebrelimab Injection trials Research Report on Adebrelimab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets - Triple Negative Breast Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1000 | 2026-09-02 | 2026-09-09 |
| A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) SHR-8068 Injection, Adebrelimab Injection, Gemcitabine Hydrochloride for Injection - Advanced Biliary Tract Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 604 | 2026-01-21 | 2026-01-28 |
Carcinoma, Non-Small-Cell Lung (1) · Triple Negative Breast Neoplasms (1)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3)
China (3)